<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03377140</url>
  </required_header>
  <id_info>
    <org_study_id>6756</org_study_id>
    <nct_id>NCT03377140</nct_id>
  </id_info>
  <brief_title>The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>Evaluation of the Effects of Hesperidin Supplementation on Hepatic Enzymes, Inflammatory Factors, Lipid Profile, Blood Glucose, Insulin Sensitivity, and Hepatic Steatosis Grade in Patients With Non-alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Nutrition and Food Technology Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Nutrition and Food Technology Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of Hesperidin supplement on lipid profile, liver enzymes, inflammatory
      factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50
      patients who referred to Gastrointestinal (GI) clinic with steatosis grade 2 and 3 will be
      randomly allocated to receive placebos or 2 capsules Hesperidin for 12 weeks; both groups
      will be advised to adherence the investigators' diet and exercise program too. At the first
      and the end of the intervention, lipid profiles, liver enzymes, some inflammatory markers,
      and liver fibrosis will be assessed and compared between groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">March 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>liver fibrosis</measure>
    <time_frame>12 weeks</time_frame>
    <description>assess by fibroscan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>body mass index</measure>
    <time_frame>12 weeks</time_frame>
    <description>The body mass index (BMI) or Quetelet index is a value derived from the mass (weight) and height of an individual. The BMI is defined as the body mass divided by the square of the body height, and is universally expressed in units of kg/m2, resulting from mass in kilograms and height in metres.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Hesperidin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 capsuls of Hesperidin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsuls of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hesperidin</intervention_name>
    <description>2 capsuls</description>
    <arm_group_label>Hesperidin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control</intervention_name>
    <description>2 capsuls</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 to 70 years

          -  Body Mass Index (BMI) between 25-40

          -  Sonographic findings compatible with hepatic steatosis (degree 2 or more)

        Exclusion Criteria:

          -  Diabetes

          -  Taking any kind of antibiotics two weeks before recruitment

          -  History of alcohol consumption

          -  pregnancy or lactation

          -  Professional athletes

          -  Other liver disease (viral/etc)

          -  Use of drugs such as calcium channel blockers, high dose synthetic estrogens,
             methotrexate , amiodarone, steroids, chloroquine, immunosuppressive drugs,
             lipid-lowering agents, metformin and vitamin E

          -  A history of Hypertension, Cardiovascular disease, Pulmonary disease, Renal disease &amp;
             Celiac disease; Cirrhosis

          -  History of Upper GI surgery / Prior surgical procedures such as jejunoileal or
             jejunocolic bypass, gastroplasty

          -  Following program to lose weight in recent 3 mo

          -  A history of hypothyroidism or Cushing's syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>azita Hekmatdoost, MD.PhD</last_name>
    <phone>+98-21-22077424</phone>
    <email>a_hekmat2000@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Nutrition and Food Technology Research Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azits Hekmatdoost</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Nutrition and Food Technology Institute</investigator_affiliation>
    <investigator_full_name>Dr Azita Hekmatdoost</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

